Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide
Drug: glimepiride

First Posted Date: 2012-01-13

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 196

Registration Number: NCT01509755

Locations: 🇬🇧
Novo Nordisk Investigational Site, Worksop, United Kingdom

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-13

Last Posted Date: 2024-02-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 19

Registration Number: NCT01509742

Locations: 🇩🇪
Novo Nordisk Investigational Site, Bad Lauterberg, Germany

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2012-01-12

Last Posted Date: 2023-11-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT01508949

Locations: 🇩🇰
Novo Nordisk Investigational Site, Frederiksberg C, Denmark

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-12

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 17

Registration Number: NCT01508923

Locations: 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark

Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide
Drug: placebo
Drug: levonorgestrel / ethinylestradiol

First Posted Date: 2012-01-12

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01508858

Locations: 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2012-01-12

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01508806

Locations: 🇦🇺
Novo Nordisk Investigational Site, Christchurch, Australia

Comparison of Two Liraglutide Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide

First Posted Date: 2012-01-12

Last Posted Date: 2024-01-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01508897

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neu-Ulm, Germany

Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

Completed

Conditions: Menopause
Postmenopausal Vaginal Atrophy

Interventions: Drug: estradiol, 25 mcg

First Posted Date: 2012-01-11

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1613

Registration Number: NCT01507454

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide

First Posted Date: 2012-01-10

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01507337

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-10

Last Posted Date: 2023-11-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01507285

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy